Accéder au contenu
Merck

Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors.

European journal of pharmacology (2012-06-05)
M E Choudhury, K Sugimoto, M Kubo, H Iwaki, T Tsujii, W T Kyaw, N Nishikawa, M Nagai, J Tanaka, M Nomoto
RÉSUMÉ

Zonisamide has been proven as an effective drug for the recovery of degenerating dopaminergic neurons in the animal models of Parkinson's disease. However, several lines of evidence have questioned the neuroprotective capacity of zonisamide in animal models of Parkinson's disease. Although it suppresses dopaminergic neurodegeneration in animal models, the cellular and molecular mechanisms underlying the effectiveness of zonisamide are not fully understood. The current study demonstrates the effects of zonisamide on astrocyte cultures and two 6-hydroxydopamine-induced models of Parkinson's disease. Using primary astrocyte cultures, we showed that zonisamide up-regulated the expression of mRNA encoding mesencephalic astrocyte-derived neurotrophic factor, vascular endothelial growth factor, proliferating cell nuclear antigen, metallothionein-2, copper/zinc superoxide dismutase, and manganese superoxide dismutase. Similar responses to zonisamide were found in substantia nigra where the rats were pre-treated with 6-hydroxydopamine. Notably, pharmacological inhibition of 6-hydroxydopamine-induced toxicity by zonisamide pre-treatment was also confirmed using rat mesencephalic organotypic slice cultures of substantia nigra. In addition to this, zonisamide post-treatment also attenuated the nigral tyrosine hydroxylase-positive neuronal loss induced by 6-hydroxydopamine. Taken together, these studies demonstrate that zonisamide protected dopamine neurons in two Parkinson's disease models through a novel mechanism, namely increasing the expression of some important astrocyte-mediated neurotrophic and anti-oxidative factors.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Zonisamide sodium salt, ≥98% (HPLC), powder
Supelco
Zonisamide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®